Initiate Cabergoline Therapy
The most appropriate next step is to start dopamine agonist therapy with cabergoline to treat this symptomatic prolactin-secreting microadenoma. This 60-year-old male has a confirmed prolactinoma (6 mm microadenoma on MRI) causing symptomatic galactorrhea, and the Endocrine Society strongly recommends dopamine agonist therapy for all patients with symptomatic prolactin-secreting microadenomas or macroadenomas 1.
Why Cabergoline is the Treatment of Choice
Cabergoline is specifically recommended over other dopamine agonists because it demonstrates superior efficacy in normalizing prolactin levels and achieving tumor shrinkage 1. The evidence shows:
- 95% normalization rate of prolactin levels in microadenoma patients treated with cabergoline (0.125–1.0 mg twice weekly for 12–24 months) 1
- 80% of men with microadenomas or macroadenomas achieve prolactin normalization with dopamine agonists 1
- 86% resolution rate of galactorrhea with dopamine agonist therapy 1
- In men specifically, cabergoline (0.5–1 mg twice weekly) restores sexual function and fertility parameters within 6 months 1
Dosing Strategy
Start cabergoline at 0.25–0.5 mg twice weekly and titrate based on prolactin response. Most patients require 0.25 to 3 mg/week total, though occasional patients may need higher doses 1.
Why Not Other Options
Surgery is not indicated as first-line therapy for prolactinomas—medical therapy is the standard of care. Surgery is reserved only for patients who are intolerant to or resistant to dopamine agonists 1.
Observation alone is inappropriate because this patient is symptomatic with galactorrhea. While asymptomatic microprolactinomas can be observed 1, symptomatic patients require treatment to prevent complications including sexual dysfunction and decreased bone density from prolonged hypogonadism 1.
Medication Review Consideration
While his current medications (atorvastatin and lisinopril) are not known to cause hyperprolactinemia 2, and the MRI confirms a structural lesion, this reinforces that the prolactinoma is the primary etiology requiring treatment.
Follow-Up Protocol
After initiating cabergoline 1:
- Check prolactin levels at 1 month to guide dose titration
- Repeat MRI in 1 year to assess tumor response
- Monitor for symptom resolution (galactorrhea should resolve in most cases)
- Assess for restoration of gonadal function if hypogonadal symptoms are present
Common Pitfall to Avoid
Do not delay treatment waiting for "spontaneous resolution" or pursue surgical consultation first. The evidence unequivocally supports medical therapy as first-line treatment for all symptomatic prolactinomas, regardless of size 1. Cabergoline has better tolerability and compliance compared to bromocriptine due to fewer side effects and less frequent dosing 1.